[en] The clinical diagnosis of cutaneous melanoma always calls for histological confirmation. In addition to the recognition of the classic aspects of the neoplasm, immunohistochemistry is determinant, in particular in the assessment of the size of the replicative compartment. Generally, the proliferation rate is indicative of the neoplastic progression and is related to the clinical growth rate of the neoplasm. It allows to distinguish high risk melanomas showing a high growth rate from those of lower malignancy associated with a restricted growth rate. In melanoma, the recruitment and progression of neoplastic cells in the cell cycle of proliferation have lost some of their controls that are normally processed by a series of key regulatory molecules. In addition, the apoptotic pathway counteracting any hyperproliferative activity is released of the dependency of specific regulated molecular mechanisms. This review summarizes the current knowledge on key molecular components involved in the deregulation of the growth fraction, cell proliferation and apoptosis in melanocytic neoplasms. The implication of cyclins and of the mitogen-activated protein kinase pathways are scrutinized. The involvement of neoplastic stem cells in the metastatic process is also discussed.
Disciplines :
Dermatology
Author, co-author :
Quatresooz, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics 2007. CA Cancer J Clin 57: 43-66, 2007.
Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I and EUROCARE-4 WorkingGroup: Recent cancer survival in Europe a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796, 2007.
Smoller BR: Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol 19: 34-40, 2006.
Crowson N, Magro CM and Mihm MC: Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol 19: S71-S87, 2006.
Brochez L, Verhaeghe E, Grosshans E, Haneke E, Piérard G, Ruiter D and Naeyaert JM: Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol 196: 459-466, 2002.
Alonso SR, Ortiz P, Pollan M, Pérez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA and Rodriguez-Peralto JL: Progression in cutaneous malignant melanoma is associated with distinct expression profiles. A tissue microarray-based study. Am J Pathol 164: 193-203, 2004.
Quatresooz P, Arrese JE, Piérard-Franchimont C and Piérard GE: Immunohistochemical aid at risk stratification of melanocytic neoplasms. Int J Oncol 24: 211-216, 2004.
Carlson JA, Ross JS, Slominski A, Linette G, Mysliborski J, Hill J and Mihm M Jr: Molecular diagnostics in melanoma. J Am Acad Dermatol 52: 743-775, 2005.
Claessens N, Piérard GE, Piérard-Franchimont C, Arrese JE and Quatresooz P: Immunohistochemical detection of incipient melanoma micrometastases. Relationship with sentinel lymph node involvement. Melanoma Res 15: 107-110, 2005.
Fecher LA, Cummings SD, Keefe MJ and Alani RM: Toward a molecular classification of melanoma. J Clin Oncol 25: 1606-1620, 2007.
Plaza JA, Suster D and Perez-Montiel D: Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol 15: 421-425, 2007.
Ohsie SJ, Sarantopoulos GP, Cochran AJ and Binder SW: Immunohistochemical characteristics of melanoma. J Cutan Pathol 35: 433-444, 2008.
Quatresooz P, Piérard-Franchimont C and Piérard GE: Highlighting the immunohistochemical profile of melanocytomas. Oncol Rep 19: 1367-1372, 2008.
Quatresooz P, Piérard-Franchimont C, Rorive A, Nizet JL, Piérard GE and the Mosan Study Group of Pigmented Neoplasms: Molecular histology on the diagnostic cutting edge between malignant melanomas and melanocytomas. Exp Rev Dermatol (In press).
Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH and Frank MH: Identification of cells initiating human melanomas. Nature 451: 345-349, 2008.
Bennett C: How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 21: 27-38, 2008.
Piérard GE, Piérard-Franchimont C, Henry C and Lapière M: The proliferative activity of cells of malignant melanomas. Am J Dermatopathol 6: S317-S324, 1984.
Soyer HP: Ki-67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters. J Cutan Pathol 18: 264-272, 1991.
Piérard-Franchimont C and Piérard GE: Karyometry of primary and metastatic malignant melanoma. A correlation with cell proliferation. Am J Dermatopathol 16: 247-252, 1994.
Boni R, Doguoglu A, Burg G, Muller B and Dummer R: MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 35: 416-418, 1996.
Piérard-Franchimont C, Arrese JE, Nikkels AF, Al Saleh W, Delvenne P and Piérard GE: Factor XIIIa-positive dermal dendrocytes and proliferative activity of cutaneous cancers. Virchows Arch 429: 43-48, 1996.
Talve LAI, Collan YUI and Ekfors TO: Nuclear morphometry, immuno-histochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. J Cutan Pathol 23: 335-343, 1996.
Sparrow LE, English DR, Taran JM and Heenan PJ: Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol 20: 12-16, 1998.
Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A, Wasilewska A, Lackowska B, Sokolowski A and Szklarski W: Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70: 150-160, 1999.
Straume O, Sviland L and Akslen LA: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 6: 1845-1853, 2000.
Frahm SO, Schubert C, Parwaresch R and Rudolp P: High proliferative activity may predict early metastasis of thin melanomas. Hum Pathol 32: 1376-1381, 2001.
Piérard GE and Piérard-Franchimont C: Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas. Eur J Cancer 33: 1888-1892, 1997.
Piérard-Franchimont C, Henry F, Heymans O and Piérard GE: Vascular retardation in dormant growth-stunted malignant melanomas. Int J Mol Med 4: 403-406, 1999.
Quatresooz P, Paquet P, Hermanns-Lê T and Piérard GE: Molecular mapping of Factor XIIIa-enriched dendrocytes in the skin. Int J Mol Med 22: 403-409, 2008.
Lipsker D: Growth rate, early detection and prevention of melanoma. Melanoma epidemiology revisited and future challenges. Arch Dermatol 142: 1638-1640, 2006.
Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, Schadendorf D and Dummer R: Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19: 290-302, 2006.
Hoek KS: DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 20: 466-484, 2007.
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D and Bastian BC: Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147, 2005.
Jönsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringner M, Guldberg P and Borg A: Genomic profiling of malignant melanoma using tiling-resolution array CGH. Oncogene 26: 4738-4748, 2007.
Rothhammer T and Bosserhoff AK: Epigenetic events in malignant melanoma. Pigment Cell Res 20: 92-111, 2007.
Stark M and Hayward N: Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 67: 2632-2642, 2007.
Malumbres M and Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231, 2001.
Georgieva J, Sinha P and Schadendorf D: Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 54: 229-235, 2001.
Florenes VA, Maelandsmo GM, Faye R, Nesland JM and Holm R: Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195: 530-536, 2001.
Florenes VA, Faye RS, Maelandsmo GM, Nesland JM and Holm R: Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 6: 3614-3620, 2000.
Bales ES, Deitrich C, Bandyopadhyay D, Schwahn DJ, Xu X, Didenko V, Leiss P, Cornad N, Pereira-Smith O, Orengo I and Medarno EE: High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 113: 1039-1046, 1999.
Talve L, Sauroja I, Collan Y, Punnonen K and Ekfors T: Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 74: 255-259, 1997.
Pavey SJ, Cummings MC, Whiteman DC, Castellano M, Walsh MD, Gabrielli BG, Green A and Hayward NK: Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 12: 539-547, 2001.
Bachmann IM, Straume O and Akslen LA: Altered expression of cell cycle regulators cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol 25: 1559-1565, 2004.
Fearfield LA, Larkin JMG, Rowe A, A'Hern R, Fischer C, Francis N, MacKie R, McCann B, Gore ME and Bunker CB: Expression of p16, CD95L and helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma. Br J Dermatol 156: 440-447, 2007.
Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM and Holm R: Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 153: 305-312, 1998.
Ivan D, Diwan AH, Esteva FJ and Prieto VG: Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod Pathol 17: 811-818, 2004.
Korabiowska M, Betke H, Kellner S, Stachura J and Schauer A: Differential expression of growth arrest, DNA damage genes and tumour suppressor gene p53 in naevi and malignant melanomas. Anticancer Res 7: 3697-3700, 1997.
Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinikainen M, Alhava EM and Kosma VM: P21WAF1/CIP1 expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer 79: 895-902, 1999.
Rhadi JM: Malignant melanoma arising from nevi, p53, p16, and bcl-2: expression in benign versus malignant components. J Cutan Med Surg 3: 293-297, 1999.
Webber BA, Lawson D and Cohen C: Maspin and mutant p53 expression in malignant melanoma and carcinoma: use of tissue microarray. Appl Immunohistochem Mol Morphol 16: 19-23, 2008.
Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz J and Reed RJ: Ki-67 and p53 expression in minimal deviation melanoma as compared with other nevomelanocytic lesions. Mod Pathol 16: 525-529, 2003.
Loggini B, Rinaldi I Pingitore R, Cristofani R, Catagna M and Barachini P: Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance. Tumori 87: 179-186, 2001.
Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, Busam K, Cordon-Cardo C and Osman I: HDM2 protein over-expression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61: 7642-7646, 2001.
Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, Cordon-Cardo C and Osman I: HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 94: 1803-1806, 2002.
Johnson G and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2001.
Ihn H: p38 MAPK inhibitors in dermatology. Expert Rev Dermatol 2: 403-407, 2007.
Giehl K: Oncogenic ras in tumour progression and metastasis. Biol Chem 386: 193-205, 2005.
Campbell PM and Der CJ: Oncogenic ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14: 105-114, 2004.
Davies H, Gibnell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber GL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
Beeram M, Patnaik A and Rowinsky EK: RAF, a strategic target for therapeutic development against cancer. J Clin Oncol 23: 6771-6790, 2005.
Johansson P, Pavey S and Hayward N: Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res 20: 216-221, 2007.
Marshall CJ: MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 4: 82-89, 1994.
Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH and Stephenson JR: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci USA 80: 4218-4222, 1983.
Pollock PM, Harper UL, Hansen KS, Yudt LM, Sark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Phoida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM and Meltzer PS: High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20, 2003.
Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, Mason G, Magee J, Angel C, Dobrovic A and McArthur GA: Distinct clinical and pathological features are associated with BRAF mutation in primary melanoma. J Invest Dermatol 127: 900-905, 2007.
Pollock PM and Meltzer PS: A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2: 5-7, 2002.
Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR and Weber BL: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000, 2002.
Brozyna A, Zbytek B, Granese J, Carlson JA, Ross J and Slominski A: Mechanism of UV-related carcinogenesis and its contribution to nevi/ melanoma. Expert Rev Dermatol 2: 451-469, 2007.
Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rütten A, Mentzel T, Hügel H, Hantschke M, Schmid-Wendtner MH, Kutzner H and Sander CA: Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121: 1160-1162, 2003.
Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D and Bastian BC: Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95: 1878-1890, 2003.
Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Goetz R and Rapp UR: Constitutive activation of the ras-raf signalling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6, 2004.
Lang J and MacKie RM: Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral and lentigo maligna subtypes. J Invest Dermatol 125: 575-579, 2005.
Cohen Y, Rosenbaum E, Begum S, Goldenberg D, Esche C, Lavie O, Sidransky D and Westra WH: Exon 15 BRAF mutations are uncommon in melanomas arising in non sun-exposed sites. Clin Cancer Res 15: 3444-3447, 2004.
Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kantesky PA, Pinkel D and Bastian BC: MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313: 521-522, 2006.
Pho L, Grossman D and Leachman SA: Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 18: 173-179, 2006.
Lin N, Urabe K, Moroi Y, Uchi H, Nakahara T, Dainichi T, Kokuba H, Tu Y and Furue M: Overexpression of phosphorylated-STAT3 and phosphorylated-ERK protein in dermatofibrosarcoma protuberans. Eur J Dermatol 16: 262-265, 2006.
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN and Bacus SS: Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100: 499-506, 2004.
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, van Belle PA, Xu X, Elder DE and Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337, 2005.
Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, Vervaert CE and Seigler HF: Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126: 142-153, 2006.
Buac K and Pavan WJ: Stem cells of the melanocyte lineage. Cancer Biomark 3: 203-209, 2007.
Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ and Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102-107, 2007.
Schatton T and Franck MH: Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 21: 39-55, 2007.
Rappa G, Fodstad O and Lorico A: The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26: 2008-3017, 2008.
Hussein M, Haemel A and Wood ES: Apoptosis and melanoma: molecular mechanisms. J Pathol 199: 275-288, 2003.
Sprecher E, Bergman R, Meilick A, Kerner H, Manov L, Reiter I, Shafer Y, Maor G and Friedman-Birnbaum R: Apoptosis, Fas and Fas-ligand expression in melanocytic tumors. J Cutan Pathol 26: 72-77, 1999.
